Helius Med Technologies Inc Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Dr. Antonella Favit-Van Pelt as Chief Medical Officer. Dr. Favit-Van Pelt brings over 20 years of experience in neurology and medical program leadership. Her expertise will support the advancement of PoNS technology, highlighted by recent U.S. regulatory clearance for treating multiple sclerosis. As part of her induction, she received options for 18,000 shares, priced at $16.45 with a four-year vesting schedule. Helius aims to enhance awareness and expand its clinical and regulatory strategies under her leadership.

Helius Medical Technologies has announced its participation in the Annual World Congress of the Society for Brain Mapping and Therapeutics from July 8-11, 2021, in Los Angeles. The company will receive the Pioneer in Technology Award, recognizing its innovative contributions to neurotechnology. Co-Founder Dr. Jonathan Sackier will present on the PoNS™ device, highlighting its role in treating gait deficits associated with conditions like multiple sclerosis. This non-surgical device delivers electrical stimulation through the tongue, showing promise in enhancing neurological wellness.

Helius Medical Technologies (NASDAQ:HSDT) announced that it will release its second quarter fiscal year 2021 financial results on August 12, 2021, after market close. Management will host a conference call at 5:00 p.m. ET to discuss the results, accessible via phone and a live webcast. The PoNS™ device is currently authorized for treatment of gait deficit from multiple sclerosis in the U.S. and is available for similar conditions in Canada. For more details, visit the company's investor relations website.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced the appointment of Dane C. Andreeff as President and CEO and Jeffrey S. Mathiesen as CFO, effective June 14, 2021. Andreeff has served as Interim CEO since August 2020 and Mathiesen has experience in CFO roles across technology-based companies for nearly 30 years. The board expressed confidence in their leadership capabilities to guide Helius through a critical growth phase, focusing on the PoNS™ technology aimed at improving disabilities related to multiple sclerosis.

Helius Medical Technologies, a neurotech company, will participate in Noble Capital Markets’ Virtual Road Show Series on June 10, 2021. The event will feature a corporate presentation followed by a Q&A session led by Senior Research Analyst Joe Gomes. Interested parties can register for the live webcast at 1:00 p.m. Eastern Time, and a recording will be available afterwards. Helius is focused on developing non-invasive technologies that enhance neurological wellness, including the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.

Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Frederick Fantazzia as Vice President of Sales & Marketing for North America, effective June 1, 2021. Fantazzia brings 16 years of experience in the neuromodulation field, previously serving at LivaNova. He aims to develop the market for Helius’s PoNS Treatment, authorized for sale in the U.S. for multiple sclerosis patients experiencing gait deficit. This leadership change comes as the company prepares for commercialization efforts.

Helius Medical Technologies (Nasdaq:HSDT) reported Q1 2021 results showing a net loss of $3.4 million, down from $4.8 million a year prior. Revenue was $84,000 compared to $207,000 in the same quarter last year. The company received FDA marketing authorization for its Portable Neuromodulation Stimulator (PoNS™) for treating gait deficits in MS patients. Cash reserves increased to $11.4 million, up from $3.3 million at year-end 2020. Helius aims to commercialize PoNS in the U.S. in Q1 2022, while addressing reimbursement strategies following recent CMS announcements.

Helius Medical Technologies (Nasdaq:HSDT) announced participation in the Planet MicroCap Showcase from April 20-22, 2021. Management will present on April 21 at 8:30 a.m. ET. A live audio webcast of the presentation will be accessible on the investor relations website under the 'Events' section. Helius is a neurotech company dedicated to promoting neurological wellness through innovative technologies like the Portable Neuromodulation Stimulator (PoNS™), which aids in treating gait deficits due to multiple sclerosis. More details are available on their official website.

Helius Medical Technologies (NASDAQ:HSDT) announced its upcoming release of Q1 fiscal year 2021 financial results on May 17, 2021, after market close. Management will host a conference call at 5:00 PM ET to discuss the results. The Portable Neuromodulation Stimulator (PoNS™), Helius's main product, is utilized for treating gait deficits related to multiple sclerosis. The device is approved for use in the U.S. and Canada, while it remains investigational in the EU and Australia. Further details are available on Helius's investor relations website.